mi2

MI-2 (Menin-MLL Inhibitor) is an effective menin-MLL interaction inhibitor (IC50: 446 ± 28 nM).

MI-2 (MALT1 inhibitor) is an irreversible MALT1 inhibitor.

Menin-MLL inhibitor MI-2 (MI2) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.

OSMI-2 is a cell-permeable inhibitor of O-linked N-acetylglucosamine transferase (OGT).

MI-217 is an effective SIRT3 inhibitor that induces apoptosis in MDA-MB-231 cells. It is applicable for breast cancer research.

Menin-MLL inhibitor MI-2 dihydrochloride is a competitive and selective inhibitor of the Menin-MLL interaction, with an IC50 value of 446 nM and a Ki value of 158 nM. It reduces the expression of target genes such as HOXA9 and MEIS1, inhibits the proliferation of leukemic cells, and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 dihydrochloride shows potential for research in MLL-rearranged acute leukemias, such as acute myeloid leukemia and acute lymphoblastic leukemia.

MI-2-80 is a molecular glue degrader that induces the binding of proteins such as IKZF1/3 and CSNK1A1 to CRBN, thereby promoting their ubiquitination and degradation.

p18SMI-21 is a novel INK4C inhibitor. It also specifically blocking the bioactivity of p18 protein.

MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM.

p18SMI-22 is an INK4C inhibitor.

MI-219 is a human double minute 2 (HDM2) inhibitor.

MI-223 is an inhibitor of Mcl-1-stimulated homologous recombination (HR) DNA repair, which leads to sensitization of cancer cells to hydroxyurea- or olaparib-induced DNA replication stress.

Epirubicin (4'-Epidoxorubicin) is an anthracycline antibiotic that acts as a Topoisomerase II inhibitor. It exerts its antitumor effects by intercalating into DNA base pairs, inhibiting DNA replication and transcription, and inducing DNA strand breaks/apoptosis. Epirubicin is widely used in the treatment of breast, gastric, lung, and ovarian cancers.

Dolispan is a Histamine H1 Antagonist.